EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Computer‐Aided Design of VEGFR ‐2 Inhibitors as Anticancer Agents: A Review

Abdullahi Ibrahim Uba iD

Journal of Molecular Recognition · 2025

DOI: 10.1002/jmr.3104 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Molecular Recognition, 2025. Verfasst von Abdullahi Ibrahim Uba. Beteiligte Einrichtung: Department of Molecular Biology and Genetics, Istanbul AREL University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Antineoplastic Agents, Computer-Aided Design, Drug Design. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 166 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Due to its intricate molecular and structural characteristics, vascular endothelial growth factor receptor 2 (VEGFR‐2) is essential for the development of new blood vessels in various pathological processes and conditions, especially in cancers. VEGFR‐2 inhibitors have demonstrated significant anticancer effects by blocking many signaling pathways linked to tumor growth, metastasis, and angiogenesis. Several small compounds, including the well‐tolerated sunitinib and sorafenib, have been approved as VEGFR‐2 inhibitors. However, the widespread side effects linked to these VEGFR‐2 inhibitors—hypertension, epistaxis, proteinuria, and upper respiratory infection—motivate researchers to search for new VEGFR‐2 inhibitors with better pharmacokinetic profiles. The key molecular interactions required for the interaction of the small molecules with the protein target to produce the desired pharmacological effects are identified using computer‐aided drug design (CADD) methods such as pharmacophore and QSAR modeling, structure‐based virtual screening, molecular docking, molecular dynamics (MD) simulation coupled with MM/PB(GB)SA, and other computational strategies. This review discusses the applications of these methods for VEGFR‐2 inhibitor design. Future VEGFR‐2 inhibitor designs may be influenced by this review, which focuses on the current trends of using multiple screening layers to design better inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor Receptor-2Antineoplastic AgentsComputer-Aided DesignDrug DesignQuantitative Structure-Activity RelationshipProtein Kinase InhibitorsMolecular Dynamics SimulationHumansMolecular Docking SimulationNeoplasms

Stichwörter der Autor:innen

CADD methodsVEGFR‐2VEGFR‐2 inhibitorsanticancer agentsmultilayered strategy

Substanzen

Vascular Endothelial Growth Factor Receptor-2Antineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Molecular Biology and Genetics, Istanbul AREL University, Istanbul, Turkey.

ORCID-Profile: Abdullahi Ibrahim Uba

Zitieren

APA

Uba, A. I. (2025). Computer‐Aided Design of VEGFR ‐2 Inhibitors as Anticancer Agents: A Review. Journal of Molecular Recognition. https://doi.org/10.1002/jmr.3104

Vancouver

Uba AI. Computer‐Aided Design of VEGFR ‐2 Inhibitors as Anticancer Agents: A Review. Journal of Molecular Recognition. 2025. doi:10.1002/jmr.3104

BibTeX
@article{Uba2025,
  author = {Uba, Abdullahi Ibrahim},
  title = {Computer‐Aided Design of VEGFR ‐2 Inhibitors as Anticancer Agents: A Review},
  journal = {Journal of Molecular Recognition},
  year = {2025},
  doi = {10.1002/jmr.3104}
}
Kostenlos starten →